TNF and psoriasis vulgaris: The DERMBIO registry of 2161 Danish patients with moderate to severe plaque psoriasis evaluated the safety of ustekinumab (n = 1055), compared to TNF-α inhibitors (adalimumab, etanercept, and infliximab) [78].